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Tumor imaging is a rapidly growing and important area of medical research. COX-2 is an 
enzyme found in large quantities in tumors, and its inhibitors are of special interest as carrier 
molecules of radiolabeled atoms for PET scans of the body. Fluorine-18 is a commonly used 
PET isotope because its half-life of 110 minutes provides an adequate amount of time to 
incorporate it into appropriate PET imaging molecules, but it does not cause as much damage 
from radiation as other longer lasting isotopes.  The present study describes the synthesis and 
radiofluorination of a novel COX-2 inhibitor analog, 2-(4-(2-(4-
(methylsulfonyl)phenyl)cyclopent-1-enyl)phenoxy)ethyl methanesulfonate, for use in PET scans 
as a potential imaging agent. The synthesis was accomplished first through the creation of a 
diaryl heterocycle via two Suzuki coupling reactions and then through the addition of a mesylate 
leaving group, which was exchanged with 18F to give the desired compound. This reaction 











Chapter 1: Introduction 
 
The inflammatory process is a crucial part of how the body deals with infection and 
irregularities in homeostasis.1 Cyclooxygenase (COX), also known as prostaglandin G/H 
synthase, is an enzyme which is recruited to the site of inflammation during such a process and 
acts by catalyzing the reaction of arachidonic acid to prostanoids such as prostaglandins and 
thromboxanes.2 These prostanoids are responsible for downstream effects of many physiologic 
responses. COX exists in multiple forms, the most common being the constitutive and induced 
forms, termed COX-1 and COX-2 respectively. COX-2 is located primarily in the brain and 
kidney and is transiently expressed in response to stimuli such as cytokines, growth factors, and 
hormones. COX-2 has also been shown to be overexpressed in many types of cancer.3 COX-1, 
however, is normally expressed in most resting tissues and serves a protective function in 
maintaining the integrity and homeostasis of the gastric and renal systems.4  
Some of the most common drugs which work to reduce pain and the inflammatory 
response are the nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and 
naproxen, which compete for the active site of COX enzymes and effectively block their 
function. However, while the functions of the two forms of COX are different, their structure and 
action are very similar. NSAIDs not only block the inflammatory response of COX-2 but also 
disrupt the constitutive expression of COX-1.5 Long term COX-1 inhibition and use of NSAIDs 
has been found to cause serious health defects especially relating to the gastric tract (stomach 
ulcers, etc.), as the protective abilities of COX-1 are suspended.6 Therefore, the need for drugs 
which reduce or eliminate these harmful side effects spurred the search for COX-2 selective 
inhibitors. The first to be discovered was DuP-697, an anti-inflammatory agent which did not 
produce negative gastric side effects.7 It was discovered that, though COX-1 and COX-2 have 
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very similar structures, the active site of COX-2 has an extra “pocket” and is slightly larger. The 
diaryl heterocyclic structure of DuP-697 was found to fit very well in both the main active site 
and the extra “pocket” while having poor affinity for the COX-1 active site.8 The binding 
kinetics and selectivity of COX-2 over COX-1 enzymes can be controlled by modifying certain 
points in this base structure. It was found that at least one of the phenyl substituents of the 
compound should have a sulfonyl or sulfonamide group in the para position for greatest COX-2 
selectivity and other sites could be changed as well, including the components of the heterocycle 
itself.9 Many such preferential drugs have since been developed using the diaryl heterocyclic 
structure as a base, including Celecoxib, Rofecoxib and Valdecoxib, Figure 1. It should be noted 
that the structure of these molecules is of great importance since unexpected physiological 
responses may occur as observer for Rofecoxib. This drug was taken off the market after studies 
showed increased adverse cardiovascular events in patients with coronary artery disease. This is 
due to the ability of Rofecoxib to act as a weak base, and easily oxidized.10 
 




 As previously noted, overexpression of COX-2 is involved in cancer. The inflammatory 
process is triggered when a cell begins to divide out of control, recruiting a variety of molecules 
to the site. COX-2 in particular has been implicated in multiple steps of cancer progression 
including its initiation, proliferation, and metastasis. Mechanisms that have been proposed for its 
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involvement deal with increased production of PGE2 by the overexpressed COX-2. It has been 
shown to be a factor in the effective blockage of programmed cell death and anticancer 
treatments, and through the creation of reactive oxygen species which cause DNA damage and 
mutations. Increased PGE2 is most often associated with colon, breast, and lung cancers and has 
recently been found to be associated with some lymphomas as well.11-13 Radiolabeled COX-2 
inhibitors, therefore, are considered to be very effective candidates for visualization of tumors 
and cancer metastases.   
 Positron emission tomography (PET) is a broadly used method of imaging biological and 
molecular processes. In particular, it is useful in research and nuclear medicine.14 PET functions 
through the use of a radiolabeled molecule such as biologically active small molecules, peptides, 
ligands, or enzyme inhibitors which localize at a site of interest. The radioactive atom attached to 
the biologically active molecule emits positrons which decay into to photons travelling in 
opposite (nearly 180⁰) directions that can be traced back to the point of origin to form an 
image.15 Fluorine-18 is a popular radiotracer because of its half-life of 110 minutes, keeping the 
radioactive material from lingering too long in the body, and because it can be easily attached to 
molecules found normally in the body. Other radioactive elements such as 124I have also been 
studied but are less efficient, have longer half-lives, and produce higher energy gamma rays 
which expose patients to higher levels of radiation and decrease the quality of the image.16  
The need for a variety of biological molecules which can be easily radiolabeled for PET 
imaging has caused a surge in research in this area of nuclear medicine. COX-2 inhibitor analogs 
in particular have been of interest because of their presence in tumors. Many of those previously 
synthesized had low success rates due to the properties of the molecule chosen or because they 
required a large amount of time to incorporate the 18F into the molecule, reducing their 
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effectiveness. This has led to the study of the factors which will increase the success of this 
reaction. It has been found that aliphatic nucleophilic substitutions of 18F into target molecules 
are particularly useful, efficient, and easy to prepare if a good leaving group such as a halogen or 
sulfonate is present in the molecule.16 Sulfonic acid esters (such as tosylate or mesylate 
functionalities) have high reactivity and can be easily synthesized without threatening the 
structural integrity of the molecule. In addition to modifying and optimizing the site of reaction, 
the base molecule can be modified to make the reaction easier. In particular, 1,2-
diarylcyclopentenes and their derivatives have shown to be effective structural motifs in COX-2 
inhibitors by having increased selectivity over COX-1 inhibitors.18 
The present study aims to improve upon the radiolabeling procedure presented by Laube, 
et al.19 in which a ditosylate is first radiolabeled with 18F and then attached to 4-(2-(4-
methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol (compound 6). This method, though 
successful, is lengthy, and limits the time available from when the radiotracer is incorporated 
into the molecule to the time of use. By synthesizing the radiolabeled precursor in its entirety 

















Chapter 2: Experimental Procedure 
 
2.1 Synthesis Overview 
 The synthesis of the precursor molecule 7 for radiolabeling is shown in the reaction 
scheme presented in Figure 2 below. It was carried out in four steps, involving the creation of a 
1,2-diarylcyclopentene through two Suzuki cross-coupling reactions, the conversion of the 
methoxy group to a hydroxyl moiety, and finally the addition of the bromoethyl 
methanesulfonate. The general procedure used was based on a modification of that given by 
Wuest, et al.20 All non-radioactive compounds were purified by flash chromatography as 
outlined by Still, et al21 and analyzed by 1H-NMR spectroscopy. Precursor 7 was then labeled 
with 18F.  The radiolabeled compound 8 was analyzed by radio-TLC (see appendix for spectra).  
 








2.2 Synthesis of 1-(2-Bromocyclopent-1-enyl)-4-methoxybenzene (3) 
 
The starting materials, 1,2-dibromocyclopentene, 1, (1.0 g, 4.4 mmol) and 4-
methoxyphenyl boronic acid 2 (336 mg, 2.20 mmol) were added to a roundbottomed flask. 
Toluene, ethanol, and 2M sodium carbonate were then added in a 1:1:1 ratio using 30 mL of each 
reagent. The roundbottomed flask was then capped and vacuum was applied for 15 minutes to 
remove any dissolved oxygen. The Pd(PPh3)4 catalyst (127 mg, 0.110 mmol) was then carefully 
added with the resulting solution placed under argon atmosphere and refluxed for 2 hours at 90 
⁰C with stirring. The reaction progress was monitored by thin layer chromatography (TLC, 50% 
ethyl acetate/hexanes) every 30 minutes until completion. After the reaction was complete, 250 
mL of water was added and the product solution was extracted with ethyl acetate. The ethyl 
acetate extract was then dried over anhydrous sodium sulfate and a rotary evaporator was used to 
remove the solvent. The residue was then purified by flash chromatography (50% ethyl 
acetate/hexanes), checking for the presence of the desired compound 3 in each fraction by TLC. 
The fractions containing 3 were then placed on the rotary evaporator to give 330 mg of a yellow 





Figure 3. Reaction scheme for first Suzuki coupling reaction. 
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2.3 Synthesis of 1-Methoxy-4-(2-(4-(methansulfonyl)phenyl)cyclopent-1-
enyl)-benzene (5) 
 
The starting materials 1-(2-bromocyclopent-1-enyl)-4-methoxybenzene, 3, (300 mg, 1.18 
mmol) and 4-(methylsulfonyl)phenylboronic acid 4 (236.8 mg, 1.18 mmol) were added to a 
roundbottomed flask. Toluene, ethanol, and 2M aqueous sodium carbonate were then added in a 
1:1:1 ratio of 16 mL each. The roundbottomed flask was then capped and placed under vacuum 
for 15 minutes to remove any dissolved oxygen. The Pd(PPh3)4 catalyst (70 mg, 0.06 mmol) was 
then carefully added with the resulting solution placed under argon atmosphere and refluxed for 
1 hour at 90 ⁰C with stirring. The reaction progress was monitored by TLC (50% ethyl 
acetate/hexanes) every 30 minutes until completion. After the reaction was complete, 100 mL of 
water was added and the product solution was extracted with ethyl acetate. The ethyl acetate 
extract was then dried over anhydrous sodium sulfate and a rotary evaporator was used to 
remove the solvent. The residue was then purified by flash chromatography (50% ethyl 
acetate/hexanes), checking for the presence of the desired compound 5 in each fraction by TLC. 
The fractions containing 5 were then placed on the rotary evaporator to give 112 mg of a 
white/yellow solid with a melting point of 128-130 ⁰C. The reaction yield was 29%. 
 




2.4 Synthesis of 4-(2-(4-Methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol 
(6) 
1-Methoxy-4-(2-(4-(methansulfonyl)phenyl)cyclopent-1-enyl)-benzene, 5, (112 mg, 0.34 
mmol) was dissolved in 1.3 mL of dichloromethane in a stirring roundbottomed flask. The 
mixture was cooled to -78 ⁰C in a dry ice/acetone bath and 1M boron tribromide in 
dichloromethane (0.39 mL, 0.39 mmol) was added, turning the solution brown. The solution was 
then warmed to room temperature and allowed to stir for one hour, monitoring the reaction 
progress by TLC (30% ethyl acetate/hexanes). The solution was again cooled to -78 ⁰C using a 
dry ice/acetone bath and 0.65 mL of methanol was added, turning the solution a dark green, 
before warming the mixture to 0 ⁰C in an ice water bath for an additional hour. The solvent was 
then evaporated using a rotary evaporator and the compound was purified by flash 
chromatography (30% ethyl acetate/hexanes), checking for the presence of the desired compound 
6 in each fraction by TLC. The fractions containing 6 were then placed on the rotary evaporator 
to give 48 mg of a solid with a melting point of 154-156 ⁰C. The reaction yield was 45%. 
 




2.5 Synthesis of 2-(4-(2-(4-(Methylsulfonyl)phenyl)cyclopent-1-
enyl)phenoxy)ethyl methanesulfonate (7) 
4-(2-(4-Methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol, 6, (48 mg, 0.15mmol) was 
dissolved in a roundbottomed flask in 5 mL of acetone. Cesium carbonate (73.3 mg, 0.225 
mmol) and 2-bromoethyl methanesulfonate (45 mg, 0.23 mmol) were then added and the 
resulting solution was placed under argon atmosphere and refluxed and stirred at 50 ⁰C in an oil 
bath for 3 hours. The reaction progress was monitored by TLC (20% ethyl acetate/hexanes) 
every 30 minutes until completion. The resulting product was then put on a rotary evaporator to 
remove the solvent. The residue was then purified by flash chromatography (20% ethyl 
acetate/hexanes), checking for the presence of the final compound 7 in each fraction by TLC. 
The fractions containing 7 were then placed on the rotary evaporator to give 17 mg of a liquid. 
The reaction yield was 26%. 
 






2.6 Synthesis of 1-(2-(Fluoro-18F)ethoxy)-4-(2-(4-
(methylsulfonyl)phenyl)cyclopent-1-enyl)benzene (8) 
The final step in this reaction scheme involves the radiolabeling of                       
precursor 7 with fluorine-18. 2-(4-(2-(4-(Methylsulfonyl)phenyl)cyclopent-1-enyl)phenoxy)ethyl 
methanesulfonate 7 (4.0 mg, 9.2 µmol) was dissolved in t-amyl alcohol (0.75 mL), acetonitrile 
(0.083 mL) and DMF (0.17 mL) before adding a Kryptofix-2.2.2,  potassium carbonate, and 
[18F]fluoride to the mixture.  The radiofluorination was carried out at 100⁰C for 20 minutes. 
Unreacted fluoride was then removed by adding 5 mL of water to the reaction and passing it 
through an alumina N Sep-Pak cartridge. A radio-TLC of the product was carried out in 60% 
ethylacetate/40% hexanes and determined an overall non-decay corrected radiochemical yield of 




















Chapter 3: Discussion and Conclusions 
 
 The synthesis of compound 8 was successfully completed using the method described 
above. However, a few revisions from the originally planned experimental procedure were 
necessary for the complete synthesis of 8.  
The Suzuki coupling reaction steps for synthesis of 3 and 5 were originally planned to 
utilize refluxing conditions for 24 hours as described by Wuest, et al. However, TLC analysis 
during the first two hours of each reaction showed that the reactants were consumed and a 
product was formed. The reaction was allowed to run for the full 24 hours, but all of the desired 
product was completely dehalogenated upon spectral analysis, indicating too long of a reaction 
time. The reaction was run again and monitored very carefully by TLC, and was stopped after 2 
hours when all reactant was converted to product. This unexpected phenomenon was likely due 
to the removal of dissolved oxygen before adding the catalyst during this experiment, a step 
which was not outlined in the paper by Wuest, et al. The 
tetrakis(triphenylphosphine)palladium(0) catalyst is highly sensitive to oxygen and light and is 
not optimally active when these factors are present.22 This is believed to be the reason for the 
better action of the catalyst and therefore the faster reaction time during the present experiment.  
Another complication encountered during the experiment was in the synthesis of 7. As 
the purpose of this experiment was to improve upon the radiolabeling method presented by 
Laube, et al., the same leaving group, ethylen-1,2-ditosylate, was originally used during the 
synthesis of 7. However, upon spectral analysis, there was no evidence of the correct product 7 
and excess ditosylate was found to be present. This led to the conclusion that 6 reacted twice 
with the ditosylate, displacing both tosylate groups and creating an undesired product. This 
possibility was considered during the experimental design and to be avoided by using 2.5 
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equivalents of the ditosylate as compared to 6, but this did not appear to have stopped the 
undesired reaction from occurring. Consequently, 2-bromoethyl methanesulfonate was used in 
place of the ethylen-1,2-ditosylate. This compound functions in the same manner as the 
ditosylate but since only one end of the molecule has the more reactive sulfonic acid ester for 
radiofluorination, the aforementioned problem was not encountered. The mesylate group has 
actually been found to be a more reactive leaving group than the tosylate group in 18F-
fluorinations and therefore was chosen as a useful substitute for the present experiment.16  
The radiochemical yield (RCY) of 8 was 11% non-decay corrected. Previous attempts at 
creating 8 via a different method as presented by Laube, et al resulted in a decay-corrected RCY 
of 7.8%, which translates to 4.7% non-decay corrected RCY after 80 minutes as described.19 
This demonstrates that the new method  more than doubled the non-decay RCY and is thus 
provides a more efficient means of producing this compound. In general, the yields of the non-
radioactive reaction steps were lower than expected, especially when compared to those reported 
by Wuest. This is likely due human error during steps such as extraction and purification by flash 
chromatography. However, in chapter 2.5, the poor yield of 26% is likely due to a mixture of 
products formed due to the leaving group capacity of both bromine and the mesylate group. It 
should be noted that the radio-TLC of compound 8 has a small impurity at 20 mm which was 
identified as a trace of the unreacted fluoride that went through the alumina cartridge.  
While many molecules for PET scan imaging are already available, there is a growing 
demand for easier and more efficient processes by which to incorporate the precursors into radio-
labeled compounds. By synthesizing compound 6 in its entirety before fluorinating it with 18F, 
the RCY was greatly increased from the previous method of synthesis as described by Laube, et 
al and others in the literature. The improvement allows for a larger window of time from the end 
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of synthesis to potential use as a PET scan imaging agent. The present study cannot predict how 
effective compound 8 will be in vivo. It is hoped that future studies with this COX-2 inhibitor 
analog will determine its efficacy in preclinical trials on small animals such as rats to see how 
well the compound mimics COX-2 inhibitor activity. While there are several steps involved in its 
synthesis, the ease of the process combined with the advantages noted above provide a promising 
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Appendix I: NMR Spectra 
 






Spectrum 2. Proton NMR of 1-Methoxy-4-(2-(4-(methansulfonyl)phenyl)cyclopent-1-enyl)-




Spectrum 3. Proton NMR of 4-(2-(4-Methanesulfonyl-phenyl)-cyclopent-1-enyl)-phenol, 






Spectrum 4. Proton NMR of 2-(4-(2-(4-(Methylsulfonyl)phenyl)cyclopent-1-









Appendix II: Radio TLC 
 
 
Spectrum 6. Radio TLC of 1-(2-(Fluoro-18F)ethoxy)-4-(2-(4-(methylsulfonyl)phenyl)cyclopent-
1-enyl)benzene, Compound 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
